The evaluate looked at 24 papers published between 1987 and 2007, covering 22,300 individual models of data from 16 studies. 18 of the 24 papers also protected the social economic position of the families studied. The smallest study centered on 17 infants and the largest covered 8,441 individuals ranging from premature infants to 33 year-olds. They included major ongoing analysis from the united states and UK, with smaller studies from Sweden and Israel collectively. However, it is not possible to tell whether it is because the father figure is even more involved or whether the mother is able to be a better parent if she has more support at home.With the device costs included, hospital costs with Impella ranged from getting equivalent to $3,000 less than the intra-aortic balloon pump . The analyses were presented by William O’Neill, M.D., executive dean for clinical affairs at the University of Miami Miller School of Medicine and principal investigator of the PROTECT II study, at the Society for Cardiovascular Angiography Interventions 2011 Scientific Periods in Baltimore. The PROTECT II study was a prospective, multicenter, randomized trial, designed to measure a composite of major adverse events at thirty days, with 90-day follow-up in high-risk percutaneous coronary intervention sufferers requiring hemodynamic support, evaluating the Impella 2.5 to the IABP.